Tonix Pharmaceuticals Holding Corp. has released an investor presentation highlighting its current business operations and financial position. The company reports having three FDA-approved products focused on central nervous system and immunology therapeutic areas. As of September 30, 2025, Tonix holds approximately $190 million in cash and has no debt, with an expected cash runway into the first quarter of 2027. The company operates as a fully integrated organization encompassing research, development, manufacturing, and commercial activities, and maintains partnerships with major universities and the US federal government. A key focus is the commercial rollout of TONMYA for fibromyalgia, with a reported U.S. market of 10 million patients. TONMYA is offered at a wholesale acquisition cost of $1,860 for a 60-count and $930 for a 30-count package, targeting specific patient populations. The company has deployed 90 sales representatives and is focusing on 5% of healthcare providers who write the majority of fibromyalgia prescriptions. Tonix has also implemented patient access programs and integrated TONMYA into existing distribution channels with wholesalers and specialty pharmacies. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief on January 21, 2026, and is solely responsible for the information contained therein.
Comments